Logo image of AMRS

AMYRIS INC (AMRS) Stock Fundamental Analysis

NASDAQ:AMRS - Nasdaq - US03236M2008 - Common Stock - Currency: USD

0.05  -0.01 (-21.87%)

After market: 0.052 +0 (+4%)

Fundamental Rating

1

Taking everything into account, AMRS scores 1 out of 10 in our fundamental rating. AMRS was compared to 85 industry peers in the Chemicals industry. AMRS has a bad profitability rating. Also its financial health evaluation is rather negative. AMRS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AMRS had negative earnings in the past year.
In the past year AMRS has reported a negative cash flow from operations.
In the past 5 years AMRS always reported negative net income.
In the past 5 years AMRS always reported negative operating cash flow.
AMRS Yearly Net Income VS EBIT VS OCF VS FCFAMRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -200M -400M -600M

1.2 Ratios

AMRS has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AMRS Yearly ROA, ROE, ROICAMRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 20K 40K 60K 80K

1.3 Margins

AMRS has a worse Gross Margin (3.38%) than 87.36% of its industry peers.
AMRS's Gross Margin has declined in the last couple of years.
AMRS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-54.8%
GM growth 5Y-38.18%
AMRS Yearly Profit, Operating, Gross MarginsAMRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

AMRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
AMRS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for AMRS is higher compared to a year ago.
AMRS Yearly Shares OutstandingAMRS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M
AMRS Yearly Total Debt VS Total AssetsAMRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

2.2 Solvency

AMRS has an Altman-Z score of -9.17. This is a bad value and indicates that AMRS is not financially healthy and even has some risk of bankruptcy.
AMRS has a worse Altman-Z score (-9.17) than 90.80% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.17
ROIC/WACCN/A
WACC1.72%
AMRS Yearly LT Debt VS Equity VS FCFAMRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 500M -500M

2.3 Liquidity

AMRS has a Current Ratio of 0.52. This is a bad value and indicates that AMRS is not financially healthy enough and could expect problems in meeting its short term obligations.
AMRS has a Current ratio of 0.52. This is amonst the worse of the industry: AMRS underperforms 94.25% of its industry peers.
A Quick Ratio of 0.29 indicates that AMRS may have some problems paying its short term obligations.
AMRS has a Quick ratio of 0.29. This is amonst the worse of the industry: AMRS underperforms 95.40% of its industry peers.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.29
AMRS Yearly Current Assets VS Current LiabilitesAMRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

AMRS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -595.83%.
The Revenue for AMRS has decreased by -32.87% in the past year. This is quite bad
Measured over the past years, AMRS shows a quite strong growth in Revenue. The Revenue has been growing by 16.14% on average per year.
EPS 1Y (TTM)-595.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
Revenue 1Y (TTM)-32.87%
Revenue growth 3Y20.93%
Revenue growth 5Y16.14%
Sales Q2Q%-2.82%

3.2 Future

AMRS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.70% yearly.
The Revenue is expected to grow by 21.11% on average over the next years. This is a very strong growth
EPS Next Y67.21%
EPS Next 2Y30.71%
EPS Next 3Y22.7%
EPS Next 5YN/A
Revenue Next Year76.61%
Revenue Next 2Y27.5%
Revenue Next 3Y26.8%
Revenue Next 5Y21.11%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AMRS Yearly Revenue VS EstimatesAMRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B
AMRS Yearly EPS VS EstimatesAMRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AMRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AMRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMRS Price Earnings VS Forward Price EarningsAMRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMRS Per share dataAMRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as AMRS's earnings are expected to grow with 22.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.71%
EPS Next 3Y22.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMRS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMYRIS INC

NASDAQ:AMRS (8/18/2023, 8:19:54 PM)

After market: 0.052 +0 (+4%)

0.05

-0.01 (-21.87%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)08-09 2023-08-09/amc
Earnings (Next)11-06 2023-11-06/amc
Inst Owners0%
Inst Owner Change-99.37%
Ins Owners4.57%
Ins Owner Change0%
Market Cap18.47M
Analysts72.86
Price Target1.74 (3380%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-40.44%
Min EPS beat(2)-80.22%
Max EPS beat(2)-0.65%
EPS beat(4)0
Avg EPS beat(4)-60.02%
Min EPS beat(4)-133.43%
Max EPS beat(4)-0.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-12.47%
Min Revenue beat(2)-28.61%
Max Revenue beat(2)3.67%
Revenue beat(4)1
Avg Revenue beat(4)-17.51%
Min Revenue beat(4)-28.61%
Max Revenue beat(4)3.67%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.07
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.67
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-1.46
FCFYN/A
OCF(TTM)-1.25
OCFYN/A
SpS0.73
BVpS-1.8
TBVpS-2.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.38%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-54.8%
GM growth 5Y-38.18%
F-Score1
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 397.44%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.29
Altman-Z -9.17
F-Score1
WACC1.72%
ROIC/WACCN/A
Cap/Depr(3y)411.87%
Cap/Depr(5y)354.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-595.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
EPS Next Y67.21%
EPS Next 2Y30.71%
EPS Next 3Y22.7%
EPS Next 5YN/A
Revenue 1Y (TTM)-32.87%
Revenue growth 3Y20.93%
Revenue growth 5Y16.14%
Sales Q2Q%-2.82%
Revenue Next Year76.61%
Revenue Next 2Y27.5%
Revenue Next 3Y26.8%
Revenue Next 5Y21.11%
EBIT growth 1Y-101.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.73%
EBIT Next 3Y23.52%
EBIT Next 5YN/A
FCF growth 1Y-1444.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2138.9%
OCF growth 3YN/A
OCF growth 5YN/A